Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 3/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6653904 | 1.00 | EPHX1 (0.41) | EPHX1TSHRALDH1A1TP53DPP4 | |
| SCHEMBL6651042 | 1.00 | EPHX1 (0.41) | EPHX1TSHRALDH1A1TP53DPP4 | |
| SCHEMBL6651921 | 1.00 | EPHX1 (0.41) | EPHX1TSHRALDH1A1TP53DPP4 | |
| SCHEMBL6650528 | 1.00 | EPHX1 (0.41) | EPHX1TSHRALDH1A1TP53DPP4 | |
| SCHEMBL15668891 | 0.85 | EPHX1 (0.48) | EPHX1ALDH1A1TP53DPP4KDM4E | |
| SCHEMBL7120046 | 0.85 | EPHX1 (0.48) | EPHX1ALDH1A1TP53DPP4KDM4E | |
| SCHEMBL27957328 | 0.84 | EPHX1 (0.43) | EPHX1ALDH1A1TP53DPP4KDM4E | |
| SCHEMBL30093936 | 0.83 | EPHX1 (0.44) | EPHX1ALDH1A1TP53DPP4KDM4E | |
| SCHEMBL16586374 | 0.80 | EPHX1 (0.40) | EPHX1ALDH1A1TP53DPP4KDM4E | |
| SCHEMBL10599727 | 0.80 | EPHX1 (0.40) | EPHX1ALDH1A1TP53DPP4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1132369-B1 | Malic acid and oxalacetic acid derivatives | DAICEL CHEM (JP) | 2004-06-09 | — | — | EP | disclosed |
| US-6489504-B2 | Malic acid and oxalacetic acid derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20010056120-A1 | Malic acid and oxalacetic acid derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-27 | — | — | US | disclosed |
| EP-1132369-A1 | Malic acid and oxalacetic acid derivatives | Daicel Chemical Industries, Ltd. (JP) | 2001-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056120-A1 | Malic acid and oxalacetic acid derivatives | ME1, ME3, MLYCD | EPHX1 3048/4885TSHR 3998/4885ALDH1A1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.